By Fineline Cube 
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced an exclusive sublicense agreement with US-based Notitia Biotechnologies, a company specializing in microbiome-targeted biotherapeutics. This collaboration grants Walvax exclusive rights to develop, manufacture, and commercialize Notitia’s proprietary gut microbiota therapy in mainland China, Hong Kong, and Macau for disease-specific populations.
Technology and Platforms
The gut microbiota therapy platform, originally licensed from Rutgers University, integrates three core technologies: core microbiota analysis, targeted microbiota transplantation, and nutritional formulation. This comprehensive approach offers broad applications in disease diagnosis, treatment prediction, inflammatory disease management, and chronic disease intervention.
Financial Terms and Commitments
Under the terms of the agreement, Walvax will make an upfront payment of USD 1 million to Notitia. Additional payments will be tied to development and sales milestones, along with long-term royalties of 6.5% of net sales.-Fineline Info & Tech